Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Novel unapproved therapies, including an antisense oligonucleotide, small interfering RNAs, and an oral small molecule have demonstrated Lp(a) reductions of up to 99% and are being tested in ongoing cardiovascular outcomes trials to determine whether pharmacologic Lp(a) lowering translates into reduced cardiovascular e...